Desvenlafaxine for the treatment of major depressive disorder

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 10, 2014, Pages 1449-1463

  Kornstein, Susan G ^a   McIntyre, Roger S ^b   Thase, Michael E ^c   Boucher, Matthieu ^d  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d PFIZER INC   (United States)

Author keywords

Adverse drug event; Desvenlafaxine; Major depressive disorder; Pharmacodynamics; Pharmacokinetics; Treatment efficacy

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; ARIPIPRAZOLE; CITALOPRAM; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DESIPRAMINE; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; KETOCONAZOLE; MIDAZOLAM; MILNACIPRAN; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PLACEBO; SERTRALINE; TAMOXIFEN; TRAZODONE; VENLAFAXINE; VORTIOXETINE;

AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; COGNITION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CLEARANCE; KIDNEY FUNCTION; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; POSTMENOPAUSE; PRACTICE GUIDELINE; QT INTERVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RELAPSE; REMISSION; SEX DIFFERENCE; SEXUAL FUNCTION; SEXUALITY; SHORT COURSE THERAPY; SIDE EFFECT; SUICIDAL IDEATION; SYSTEMATIC REVIEW (TOPIC); TIME TO MAXIMUM PLASMA CONCENTRATION; WEIGHT CHANGE; ANORGASMIA; CONSTIPATION; DECREASED APPETITE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MARKETING; DRUG PROTEIN BINDING; DRUG STRUCTURE; ERECTILE DYSFUNCTION; FATIGUE; HYPERHIDROSIS; INSOMNIA; MEDLINE; MENTAL PATIENT; MYDRIASIS; PREVENTION STUDY; QTC INTERVAL; SOMNOLENCE; TREMOR; VOMITING; XEROSTOMIA;

ADVERSE DRUG EVENT; DESVENLAFAXINE; MAJOR DEPRESSIVE DISORDER; PHARMACODYNAMICS; PHARMACOKINETICS; TREATMENT EFFICACY;

ANTIDEPRESSIVE AGENTS; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DRUG INTERACTIONS; HUMANS; RECURRENCE; SEROTONIN UPTAKE INHIBITORS;

EID: 84902282409     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.923403     Document Type: Article

References (127)

1. Rush AJ, Kilner J, Fava M, et al. Clinically relevant findings from STAR*D. Psychiatr Ann 2008;38:188-93
2. The global burden of disease. 2004 update. World Health Organization. 2008. Available from: http://www.who.int/healthinfo/global-burden-disease/2004- report-update/en/index.html [Last accessed 9 November 2012]
3. Depression. World Health Organization. 2012. Available from: http://www.who. int/mental-health/management/depression/definition/en/print.html [Last accessed 11 June 2008]
4. Patten SB, Kennedy SH, Lam RW, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. I. Classification, burden and principles of management. J Affect Disord 2009;117(Suppl 1):S5-14
5. Alonso J, Angermeyer MC, Bernert S, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004;109(420):21-7
6. Work Group on Major Depressive Disorder. Practice guideline for the treatment of patients with major depressive disorder. American Psychiatric Association, 2010. Available from: http://www.psychiatryonline.com/pracGuide/ pracGuideTopic-7.aspx [Last accessed 1 February 2012]
7. Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009;117(Suppl 1):S26-43
8. Gill JM, Klinkman MS, Chen YX. Antidepressant medication use for primary care patients with and without medical comorbidities: a national electronic health record (EHR) network study. J Am Board Fam Med 2010;23:499-508
9. Serna MC, Cruz I, Real J, et al. Duration and adherence of antidepressant treatment (2003-2007) based on prescription database. Eur Psychiatry 2010;25:206-13
10. Depression in adults. The treatment and management of depression in adults. National Institute for Health and Clinical Excellence. 2009.
11. Available from: http://www.nice.org.uk/nicemedia/live/12329/45888/45888. pdf [Last accessed 29 July 2013]
12. Milea D, Guelfucci F, Bent-Ennakhil N, et al. Antidepressant monotherapy: a claims database analysis of treatment changes and treatment duration. Clin Ther 2010;32:2057-72
13. Fava M. Management of nonresponse and intolerance: switching strategies. J Clin Psychiatry 2000;61(Suppl 2):10-12
14. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40
15. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-17
16. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48:851-5
17. Nierenberg AA, Husain MM, Trivedi MH, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med 2010;40:41-50
18. Romera I, Perez V, Menchon JM, et al. Social and occupational functioning impairment in patients in partial versus complete remission of a major depressive disorder episode. A six-month prospective epidemiological study. Eur Psychiatry 2010;25:58-65
19. D'Avanzato C, Martinez J, Attiullah N, et al. Anxiety symptoms among remitted depressed outpatients: prevalence and association with quality of life and psychosocial functioning. J Affect Disord 2013;151:401-4
20. Hardeveld F, Spijker J, De Graaf R, et al. Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatr Scand 2010;122:184-91
21. Perahia DG, Gilaberte I, Wang F, et al. Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. Br J Psychiatry 2006;188:346-53
22. Simon JS, Aguiar LM, Kunz NR, et al. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. J Psychiatr Res 2004;38:249-57
23. Entsuah AR, Rudolph RL, Hackett D, et al. Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates. Int Clin Psychopharmacol 1996;11:137-45
24. Schmidt ME, Fava M, Robinson JM, et al. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. J Clin Psychiatry 2000;61:851-7
25. Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004;65:44-9
26. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009;29:259-66
27. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010;71:1259-72
28. Preskorn SH, Flockhart D. 2006 guide to psychiatric drug interactions. Prim Psychiatry 2006;13:35-64
29. Zajecka J, Kornstein SG, Blier P. Residual symptoms in major depressive disorder: prevalence, effects, and management. J Clin Psychiatry 2013;74:407-14
30. Burra TA, Chen E, McIntyre RS, et al. Predictors of self-reported antidepressant adherence. Behav Med 2007;32:127-34
31. Sheehan DV, Keene MS, Eaddy M, et al. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders. CNS Drugs 2008;22:963-73
32. Katona CL, Katona CP. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. Neuropsychiatr Dis Treat 2014;10:349-54
33. Saraceni MM, Venci JV, Gandhi MA. Levomilnacipran (Fetzima): a new serotonin-norepinephrine reuptake inhibitor for the treatment of major depressive disorder. J Pharm Pract 2013. [Epub ahead a print]
34. Carney RM, Shelton RC. Agomelatine for the treatment of major depressive disorder. Expert Opin Pharmacother 2011;12:2411-19
35. Koesters M, Guaiana G, Cipriani A, et al. Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br J Psychiatry 2013;203:179-87
36. Brintellix [package insert]. Lundbeck Deerfield, IL; 2013
37. Fetzima [package insert]. Forest Pharmaceuticals, Inc, St. Louis, MO; 2013
38. Valdoxan summary of product characteristics. EMedicines, London, United Kingdom;, 2013
39. Pristiq [package insert]. Wyeth Pharmaceuticals, Inc, a subsidiary of Pfizer Inc, Philadelphia, PA; 2013
40. Pristiq [product monograph]. Pfizer Canada Inc, Kirkland, Quebec, Canada; 2013
41. Nichols AI, Behrle JA, Richards LS, et al. The absolute bioavailability of desvenlafaxine in healthy subjects. J Bioequiv Availab 2012;4:018-23
42. Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2006;318:657-65
43. Debonnel G, Saint-Andre E, Hebert C, et al. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol 2007;10:51-61
44. Nichols AI, Tourian KA, Tse SY, et al. Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor. Expert Opin Drug Metab Toxicol 2010;6:1565-74
45. DeMaio W, Kane CP, Nichols AI, et al. Metabolism studies of desvenlafaxine. J Bioequiv Availab 2011;3:151-60
46. Shams ME, Arneth B, Hiemke C, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 2006;31:493-502
47. Effexor XR [package insert]. Wyeth Pharmaceuticals, Inc, Philadelphia, PA; 2012
48. Nichols AI, Behrle JA, Parks V, et al. Pharmacokinetics, pharmacodynamics, and safety of desvenlafaxine, a serotonin-norepinephrine reuptake inhibitor. J Bioequiv Availab 2013;5:22-30
49. Nichols AI, Richards LS, Behrle JA, et al. Effects of age and sex on the pharmacokinetics, safety, and tolerability of oral desvenlafaxine in healthy adults. J Bioequiv Availab 2013;5:88-94
50. Nichols AI, Richards LS, Behrle JA, et al. The pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairment. Int J Clin Pharmacol Ther 2011;49:3-13
51. Baird-Bellaire S, Behrle JA, Parker VD, et al. An Open-Label, Single-Dose, Parallel-Group Study of the Effects of Chronic Hepatic Impairment on the Safety and Pharmacokinetics of Desvenlafaxine. Clin Ther 2013;35:782-94
52. Preskorn S, Patroneva A, Silman H, et al. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol 2009;29:39-43
53. Nichols AI, Focht K, Jiang Q, et al. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study. Clin Drug Investig 2011;31:155-67
54. Lobello KW, Preskorn SH, Guico-Pabia CJ, et al. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. J Clin Psychiatry 2010;71:1482-7
55. Guidance for Industry. Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. Food and Drug Administration. 2012. Available from: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatory Information/Guidances/ucm292362.pdf [Last accessed 20 May 2013]
56. Patroneva A, Connolly SM, Fatato P, et al. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Drug Metab Dispos 2008;36:2484-91
57. Nichols AI, Fatato P, Shenouda M, et al. The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol 2009;49:219-28
58. Nichols AI, Abell M, Chen Y, et al. Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults. Int Clin Psychopharmacol 2013;28:99-105
59. Nichols A, Liang Y, Matschke K, et al. An evaluation of the potential of cytochrome P450 3A4-mediated drug-drug interactions with desvenlafaxine use. J Bioequiv Availab 2013;5:53-9
60. Nichols AI, Lubaczewski S, Liang Y, et al. An open-label evaluation of the effect of coadministering desvenlafaxine 100 mg on the pharmacokinetics of aripiprazole in healthy subjects. J Bioequiv Availab 2013;5:253-9
61. Nichols AI, Lubaczewski S, Liang Y, et al. Open-label, 2-period sequential drug interaction study to evaluate the effect of a 100-mg dose of desvenlafaxine on the pharmacokinetics of tamoxifen when co-administered in healthy postmenopausal female subjects. J Clin Pharm Ther 2014;In Press
62. Oganesian A, Shilling AD, Young-Sciame R, et al. Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities. Psychopharmacol Bull 2009;42:47-63
63. Bachmeier CJ, Beaulieu-Abdelahad D, Ganey NJ, et al. Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine. Biopharm Drug Dispos 2011;32:233-44
64. Bachmeier C, Levin GM, Beaulieu-Abdelahad D, et al. Effect of venlafaxine and desvenlafaxine on drug efflux protein expression and biodistribution in vivo. J Pharm Sci 2013;102:3838-43
65. DeMartinis NA, Yeung PP, Entsuah R, et al. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 2007;68:677-88
66. Septien-Velez L, Pitrosky B, Padmanabhan SK, et al. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 2007;22:338-47
67. Liebowitz MR, Manley AL, Padmanabhan SK, et al. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin 2008;24:1877-90
68. Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 2008;23:243-53
69. Tourian KA, Padmanabhan SK, Groark J, et al. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther 2009;31 Pt 1:1405-23
70. Iwata N, Tourian KA, Hwang E, et al. Efficacy and safety of desvenlafaxine 25 and 50 mg/day in a randomized, placebo-controlled study of depressed outpatients. J Psychiatr Pract 2013;19:5-14
71. Dunlop BW, Reddy S, Yang L, et al. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol 2011;31:569-76
72. Clayton AH, Kornstein SG, Dunlop BW, et al. Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry 2013;74:1010-17
73. Liebowitz MR, Tourian KA, Hwang E, et al. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/d in adult outpatients with major depressive disorder. BMC Psychiatry 2013;13:94
74. Pae CU. Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother 2011;12:2923-8
75. Thase ME, Kornstein SG, Germain JM, et al. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr 2009;14:144-54
76. Clayton A, Tourian KA, Focht K, et al. Desvenlafaxine 50-and 100-mg/d vs placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial. J Clin Psychiatry 2014;In Press
77. Ferguson J, Tourian K, Manley A, et al. An evaluation of the efficacy, safety, and tolerability of desvenlafaxine in the long-term treatment of elderly outpatients with major depressive disorder. Prim Psychiatry 2010;17:66-73
78. Tourian KA, Pitrosky B, Padmanabhan SK, et al. A 10-month, open-label evaluation of desvenlafaxine in outpatients with major depressive disorder. Prim Care Companion CNS Disord 2011;13:e1-e10
79. Ferguson JM, Tourian KA, Rosas GR. High-dose desvenlafaxine in outpatients with major depressive disorder. CNS Spectr 2012;17:121-30
80. Tourian K, Wang Y, Ii Y. A. 10-month, open-label evaluation of desvenlafaxine in Japanese outpatients with major depressive disorder. Int Clin Psychopharmacol 2013;28:206-13
81. Rickels K, Montgomery SA, Tourian KA, et al. Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial. J Clin Psychopharmacol 2010;30:18-24
82. Rosenthal JZ, Boyer P, Vialet C, et al. Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder: a randomized controlled trial. J Clin Psychiatry 2013;74:158-66
83. Kornstein SG, Fava M, Jiang Q, et al. Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placebo. Psychopharmacol Bull 2009;42:21-35
84. Tourian KA, Jiang Q, Ninan PT. Analysis of the effect of desvenlafaxine on anxiety symptoms associated with major depressive disorder: pooled data from 9 short-term, double-blind, placebo-controlled trials. CNS Spectr 2010;15:187-93
85. Soares CN, Endicott J, Boucher M, et al. Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder. CNS Spectr 2014. [Epub ahead of print]
86. Sheehan DV. Sheehan disability scale. In: Rush AJ, Pincus HA, First MB, editors. Handbook of psychiatric measures. American Psychiatric Association, Washington, DC; 2000. p. 113-15
87. World Health Organization. Wellbeing measures in primary health care/the depcare project. World Health Organization Regional Office for Europe. 1998. Available from: http://www.euro. who.int/-data/assets/pdf-file/0016/130750/ E60246.pdf [Last accessed 20 March 2012]
88. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353-65
89. Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993;29:321-6
90. Soares CN, Kornstein SG, Thase ME, et al. Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials. J Clin Psychiatry 2009;70:1365-71
91. Lam RW, Endicott J, Hsu MA, et al. Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxine. Int Clin Psychopharmacol 2014. [Epub ahead of print]
92. Nicholson S, Sweeney M, Whiteley J, et al. Is there a business case for reducing employees' antidepressant prescription drug cost sharing? J Health Productivity 2012;6:14-22
93. Endicott J, Lam R, Hsu M-A, et al. Improvements in quality of life in employed adults treated for major depressive disorder with desvenlafaxine 50 mg/d vs placebo [poster]. Presented at: United States Psychiatric and Mental Health Congress; 8-11 November 2012; San Diego, CA
94. Reddy S, Focht K, Musgnung J, et al. The effect of desvenlafaxine on cognitive functioning in employed outpatients with major depressive disorder [poster]. Presented at: annual Meeting of the College of Psychiatric and Neurologic Pharmacists; 1-4 May 2011; Phoenix, AZ
95. Kornstein SG, Jiang Q, Reddy S, et al. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry 2010;71:1088-96
96. Soares CN, Thase ME, Clayton A, et al. Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. Menopause 2010;17:700-11
97. Soares CN, Thase ME, Clayton A, et al. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram. CNS Drugs 2011;25:227-38
98. Kornstein SG, Clayton AH, Soares CN, et al. Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder. J Clin Psychopharmacol 2010;30:294-9
99. Papakostas GI, Culpepper L, Fayyad RS, et al. Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of 6 randomized, double-blind, placebo-controlled studies. Int Clin Psychopharmacol 2013;28:312-21
100. Kornstein SG, Guico-Pabia CJ, Fayyad RS. The effect of desvenlafaxine 50 mg/d on a subpopulation of anxious/depressed patients: a pooled analysis of 7 randomized, placebo-controlled studies [poster]. Presented at: Annual New Clinical Drug Evaluation Unit Meeting; 29-May 1 June 2012; Phoenix, AZ
101. Clayton AH, Kornstein SG, Rosas G, et al. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr 2009;14:183-95
102. Montgomery SA, Fava M, Padmanabhan SK, et al. Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. Int Clin Psychopharmacol 2009;24:296-305
103. Khan A, Musgnung J, Ramey T, et al. Abrupt discontinuation compared with a 1-week taper regimen in depressed outpatients treated for 24 weeks with desvenlafaxine 50 mg/d. J Clin Psychopharmacol 2014. [Epub ahead of print]
104. Haddad PM, Anderson IM. Recognising and managing antidepressant discontinuation symptoms. Adv Psychiatr Treat 2007;13:447-57
105. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;26:25-40
106. Clayton AH, Reddy S, Focht K, et al. An evaluation of sexual functioning in employed outpatients with major depressive disorder treated with desvenlafaxine 50 mg or placebo. J Sex Med 2013;10:768-76
107. Tourian KA, Leurent C, Graepel J, et al. Desvenlafaxine and weight change in major depressive disorder. Prim Care Companion J Clin Psychiatry 2010;12:CC
108. McIntyre RS, Fayyad RS, Guico-Pabia CJ, et al. Weight change in depressed patients treated with desvenlafaxine 50 and 100 mg/d vs placebo [poster]. Presented at: United States Psychiatric and Mental Health Congress; 8-11 November 2012; San Diego, CA
109. Laughren TP. Overview for December 13 meeting of psychopharmacologic drugs advisory committee (PDAC) [memorandum]. Food and Drug Administration. 2006. Available from: http://www.fda. gov/ohrms/dockets/ac/06/briefing/2006- 4272b1-01-FDA.pdf [Last accessed 19 April 2012]
110. Tourian KA, Padmanabhan K, Groark J, et al. Retrospective analysis of suicidality in patients treated with the antidepressant desvenlafaxine. J Clin Psychopharmacol 2010;30:411-16
111. Warden D, Rush AJ, Trivedi MH, et al. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep 2007;9:449-59
112. Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry 2002;52:1166-74
113. Coleman KA, Xavier VY, Palmer TL, et al. An indirect comparison of the efficacy and safety of desvenlafaxine and venlafaxine using placebo as the common comparator. CNS Spectr 2012;17:131-41
114. Cymbalta [package insert]. Eli Lilly and Company, Indianapolis, IN; 2011
115. Schwartz TL. Metabolites: novel therapeutics or "me-too" drugs? Using desvenlafaxine as an example. CNS Spectr 2012;17:103-6
116. Eisenberg D, Isenberg KE, Gu T, et al. Treatment and healthcare utilization among commercially insured patients with major depressive disorder. Am J Pharm Benef 2013;5:e55-65
117. Allen R, Sharma U, Barlas S. Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy. J Pain Res 2014;In press
118. Archer DF, Dupont CM, Constantine GD, et al. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol 2009;200:238
119. Archer DF, Seidman L, Constantine GD, et al. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2009;200:172.e1-172.e10
120. Speroff L, Gass M, Constantine G, et al. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008;111:77-87
121. Bouchard P, Panay N, de Villiers TJ, et al. Randomized placebo-and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms. Climacteric 2012;15:12-20
122. Pinkerton JV, Constantine G, Hwang E, et al. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial. Menopause 2013;20:28-37
123. Liebowitz MR, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry 2007;68:1663-72
124. Lieberman DZ, Montgomery SA, Tourian KA, et al. A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol 2008;23:188-97
125. Feiger AD, Tourian KA, Rosas GR, et al. A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder. CNS Spectr 2009;14:41-50
126. Guico-Pabia CJ, Fayyad RS, Soares CN. Assessing the relationship between functional impairment/recovery and depression severity: a pooled analysis. Int Clin Psychopharmacol 2012;27:1-7
127. Soares CN, Fayyad RS, Guico-Pabia CJ. Early improvement in depressive symptoms with desvenlafaxine 50 mg/d as a predictor of treatment success in patients with major depressive disorder. J Clin Psychopharmacol 2014;34:57-65